CN103402514B - 用于治疗运动障碍的血清素受体激动剂组合物 - Google Patents

用于治疗运动障碍的血清素受体激动剂组合物 Download PDF

Info

Publication number
CN103402514B
CN103402514B CN201180060726.9A CN201180060726A CN103402514B CN 103402514 B CN103402514 B CN 103402514B CN 201180060726 A CN201180060726 A CN 201180060726A CN 103402514 B CN103402514 B CN 103402514B
Authority
CN
China
Prior art keywords
day
buspirone
zolmitriptan
combination
dopa
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201180060726.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN103402514A (zh
Inventor
J·B·汉森
M·S·汤姆森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CONCIT PHARMA APS
Contera Pharma AS
Original Assignee
CONCIT PHARMA APS
Contera Pharma AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CONCIT PHARMA APS, Contera Pharma AS filed Critical CONCIT PHARMA APS
Priority to CN201510595196.8A priority Critical patent/CN105193809B/zh
Publication of CN103402514A publication Critical patent/CN103402514A/zh
Application granted granted Critical
Publication of CN103402514B publication Critical patent/CN103402514B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201180060726.9A 2010-10-15 2011-10-13 用于治疗运动障碍的血清素受体激动剂组合物 Active CN103402514B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201510595196.8A CN105193809B (zh) 2010-10-15 2011-10-13 用于治疗运动障碍的血清素受体激动剂组合物

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US39354510P 2010-10-15 2010-10-15
DKPA201070441 2010-10-15
US61/393,545 2010-10-15
DKPA201070441 2010-10-15
US201161491945P 2011-06-01 2011-06-01
US61/491,945 2011-06-01
PCT/DK2011/050383 WO2012048710A1 (en) 2010-10-15 2011-10-13 Combinations of serotonin receptor agonists for treatment of movement disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201510595196.8A Division CN105193809B (zh) 2010-10-15 2011-10-13 用于治疗运动障碍的血清素受体激动剂组合物

Publications (2)

Publication Number Publication Date
CN103402514A CN103402514A (zh) 2013-11-20
CN103402514B true CN103402514B (zh) 2016-01-13

Family

ID=44883032

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201510595196.8A Active CN105193809B (zh) 2010-10-15 2011-10-13 用于治疗运动障碍的血清素受体激动剂组合物
CN201180060726.9A Active CN103402514B (zh) 2010-10-15 2011-10-13 用于治疗运动障碍的血清素受体激动剂组合物

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201510595196.8A Active CN105193809B (zh) 2010-10-15 2011-10-13 用于治疗运动障碍的血清素受体激动剂组合物

Country Status (22)

Country Link
US (2) US9186359B2 (enExample)
EP (1) EP2627328B1 (enExample)
JP (1) JP5907975B2 (enExample)
KR (1) KR101825972B1 (enExample)
CN (2) CN105193809B (enExample)
AU (1) AU2011316225B2 (enExample)
BR (1) BR112013009004B1 (enExample)
CA (1) CA2813648C (enExample)
CY (1) CY1118314T1 (enExample)
DK (1) DK2627328T3 (enExample)
ES (1) ES2602973T3 (enExample)
HR (1) HRP20161402T1 (enExample)
HU (1) HUE031661T2 (enExample)
IL (1) IL225758A (enExample)
LT (1) LT2627328T (enExample)
MX (1) MX353625B (enExample)
PL (1) PL2627328T3 (enExample)
PT (1) PT2627328T (enExample)
RS (1) RS55332B1 (enExample)
RU (1) RU2611376C2 (enExample)
SI (1) SI2627328T1 (enExample)
WO (1) WO2012048710A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2714040A1 (en) * 2011-06-01 2014-04-09 Concit Pharma ApS Combinations of serotonin receptor agonists for treatment of movement disorders
RU2670272C2 (ru) 2012-04-18 2018-10-22 Контера Фарма Апс Пероральная фармацевтическая композиция, подходящая для повышения эффективности лечения двигательных нарушений
RU2014150942A (ru) * 2012-06-11 2016-07-27 Сайкодженикс, Инк. Лечение побочных эффектов в виде моторных и двигательных расстройств, связанных с лечением болезни паркинсона
HUE039750T2 (hu) * 2014-06-26 2019-02-28 Contera Pharma Aps Hidroxi-buspiron mozgászavarok kezelésére
PT3131549T (pt) * 2014-07-09 2018-07-04 Pf Medicament Método para tratar distúrbios do movimento com befiradol
WO2016210431A1 (en) * 2015-06-26 2016-12-29 Wright State University Method of treating sepsis-induced myopathy
US11013830B2 (en) * 2015-11-20 2021-05-25 Institut Pasteur 5-hydroxytryptamine 1B receptor-stimulating agent for enhancing in vivo engraftment potential
US11975104B2 (en) 2016-07-11 2024-05-07 Contera Pharma A/S Pulsatile drug delivery system for treating morning akinesia
WO2020087031A1 (en) 2018-10-26 2020-04-30 The Research Foundation For The State University Of New York Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia
EP4335504A3 (en) 2018-12-20 2024-05-29 Contera Pharma A/S Treatment of movement disorders
EP4076433A4 (en) * 2019-12-20 2023-09-27 The Jackson Laboratory Molecular targets for addiction
CN112931397B (zh) * 2021-01-25 2024-02-27 江南大学 一种帕金森病动物模型的构建方法
KR20240004942A (ko) * 2021-05-07 2024-01-11 일라이 릴리 앤드 캄파니 2,4,6-트리플루오로-n-[6-(1-메틸-피페리딘-4-카르보닐)-피리딘-2-일]-벤즈아미드헤미숙시네이트의 맛 차폐된 조성물 및 그를 포함하는 경구 붕해 정제
CN114712365B (zh) * 2022-06-07 2022-08-23 山东绿叶制药有限公司 Trk抑制剂在制备治疗迟发性运动障碍药物中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4438119A (en) * 1982-12-23 1984-03-20 Mead Johnson & Company Method for alleviation of extrapyramidal motor disorders

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE759371A (fr) 1969-11-24 1971-05-24 Bristol Myers Co Azaspirodecanediones heterocycliques et procedes pour leur preparation
US3976776A (en) 1972-12-06 1976-08-24 Mead Johnson & Company Tranquilizer process employing N-(heteroarcyclic)piperazinylalkylazaspiroalkanediones
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4182763A (en) 1978-05-22 1980-01-08 Mead Johnson & Company Buspirone anti-anxiety method
US4356108A (en) 1979-12-20 1982-10-26 The Mead Corporation Encapsulation process
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
US4640921A (en) 1986-02-04 1987-02-03 Bristol-Myers Treatment of sexual dysfunction with buspirone
US4687772A (en) 1986-10-07 1987-08-18 Bristol-Myers Company Method for improvement of short term memory
US4777173A (en) 1987-03-25 1988-10-11 Bristol-Myers Company Method for treatment of alcohol abuse
US5185329A (en) 1988-08-30 1993-02-09 Bristol-Myers Squibb Company Method for treatment of substance addiction
US6432956B1 (en) 1990-02-12 2002-08-13 William C. Dement Method for treatment of sleep apneas
DK0486666T3 (da) 1990-06-07 1998-03-30 Zeneca Ltd Terapeutisk heterocykliske forbindelser
US5633009A (en) 1990-11-28 1997-05-27 Sano Corporation Transdermal administration of azapirones
US5431922A (en) 1991-03-05 1995-07-11 Bristol-Myers Squibb Company Method for administration of buspirone
GB9209882D0 (en) 1992-05-07 1992-06-24 Glaxo Lab Sa Compositions
US5484788A (en) 1993-03-26 1996-01-16 Beth Israel Hospital Association Buspirone as a systemic immunosuppressant
US5637314A (en) 1995-06-07 1997-06-10 Beth Israel Deaconess Medical Center, Inc. Topical and systemic application of buspirone or derivatives thereof for treating atopic dermatitis
GB9706089D0 (en) * 1997-03-24 1997-05-14 Scherer Ltd R P Pharmaceutical composition
US6150365A (en) 1999-08-05 2000-11-21 Bristol-Myers Squibb Company Anxiety method
GB9928578D0 (en) 1999-12-03 2000-02-02 Zeneca Ltd Pharmaceutical formulations
WO2002044159A2 (en) * 2000-11-29 2002-06-06 Eli Lilly And Company 1-(2-m-methanesulfonamidophenylethyl)-4-(m-trifluoromethylphenyl)piperazine and pharmaceutically acceptable salts and solvates thereof and their use in the treatment of incontinence
WO2002053139A2 (en) 2001-01-05 2002-07-11 Eli Lilly And Company Excitatory amino acid receptor antagonist and 5-ht1f agonist combination: a method for the treatment of neurological disorders
US8329734B2 (en) 2009-07-27 2012-12-11 Afgin Pharma Llc Topical therapy for migraine
US20040235920A1 (en) * 2001-09-12 2004-11-25 Gerd Bartoszyk Novel use of substituted aminomethyl chromans for the treatment of movement disorders and of adverse effects induced by drugs administered to treat extrapyramidal movement disorders
DE10353657A1 (de) 2003-11-17 2005-06-23 Merck Patent Gmbh Indolderivate
US20070173536A1 (en) 2004-02-06 2007-07-26 Ciba Specialty Chemicals Holding Inc. Crystalline forms of zolmitriptan
BRPI0514983A (pt) * 2004-09-07 2008-07-01 Pfizer combinação de um agonista do receptor 5-ht(1) e um ligante alfa-2-delta para tratamento da enxaqueca
US9066903B2 (en) 2006-02-28 2015-06-30 The United States Of America As Represented By The Department Of Veterans Affairs Pharmacological treatment of Parkinson's disease
EP2037964A2 (en) * 2006-06-16 2009-03-25 Solvay Pharmaceuticals B.V. Combination preparations comprising bifeprunox and l-dopa
TW200831479A (en) * 2006-09-26 2008-08-01 Cytrx Corp Pharmaceutical compositions and methods for treating diseases
WO2008047839A1 (en) * 2006-10-19 2008-04-24 Dainippon Sumitomo Pharma Co., Ltd. 5-ht1a receptor agonist
WO2008115797A1 (en) * 2007-03-16 2008-09-25 Pavo, Inc. Therapeutic compositions and methods
WO2009002084A2 (en) 2007-06-27 2008-12-31 Hanmi Pharm. Co., Ltd. Method for preparing rapidly disintegrating formulation for oral administration and apparatus for preparing and packing the same
EP2317996A1 (en) 2008-06-24 2011-05-11 Anders Björklund Eltoprazine for suppression of l-dopa induced dyskinesias
CN102186461A (zh) 2008-10-14 2011-09-14 麦克内尔股份公司 多部分口腔内剂型及其用途
GEP20146013B (en) 2009-01-23 2014-01-27 Aziende Chimiche Riunite Angelini Francesco A C R A F S P A It Controlled release pharmaceutical or food formulation and method of preparation thereof
US8710092B2 (en) 2009-12-23 2014-04-29 Map Pharmaceuticals, Inc. Substituted indolo 4,3 FG quinolines useful for treating migraine
EP2714040A1 (en) 2011-06-01 2014-04-09 Concit Pharma ApS Combinations of serotonin receptor agonists for treatment of movement disorders

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4438119A (en) * 1982-12-23 1984-03-20 Mead Johnson & Company Method for alleviation of extrapyramidal motor disorders

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
A serotonin 5-HT1A receptor agonist prevents behavioral sensitization to L-DOPA in a rodent model of Parkinso′s disease;Masahiko Tomiyama et al;《Neuroscience Research》;20050413(第52期);185-194 *
Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia;Ana Munoz et al.;《Brain》;20081231(第52期);2280-2294 *
Effect of 5-HT1B/D receptor agonist and antagonist administration on motor function in haloperidol and MPTP-treated common marmosets;Michael J. Jackson et al.;《Pharmacology, Biochemistry and Behavior》;20041122(第79期);391-400 *
Zolmitriptan compared to propranolol in the treatment of acute neuroleptic-induced akathisia: A comparative double-blind study;Ayelet Avital et al.;《European Neuropsychopharmacology》;20091231(第19期);476-482 *

Also Published As

Publication number Publication date
BR112013009004B1 (pt) 2022-05-10
RU2013120481A (ru) 2014-11-20
BR112013009004A8 (pt) 2017-12-26
MX2013004067A (es) 2013-07-29
SI2627328T1 (sl) 2017-01-31
US9186359B2 (en) 2015-11-17
HRP20161402T1 (hr) 2016-12-30
EP2627328B1 (en) 2016-09-14
JP2013539767A (ja) 2013-10-28
US20160058762A1 (en) 2016-03-03
CA2813648C (en) 2019-06-25
CA2813648A1 (en) 2012-04-19
US10632116B2 (en) 2020-04-28
PL2627328T3 (pl) 2017-03-31
WO2012048710A1 (en) 2012-04-19
AU2011316225B2 (en) 2016-05-19
CN103402514A (zh) 2013-11-20
PT2627328T (pt) 2016-11-23
JP5907975B2 (ja) 2016-04-26
RU2611376C2 (ru) 2017-02-21
KR101825972B1 (ko) 2018-02-06
CY1118314T1 (el) 2017-06-28
MX353625B (es) 2018-01-22
BR112013009004A2 (pt) 2016-07-05
DK2627328T3 (en) 2016-12-12
ES2602973T3 (es) 2017-02-23
LT2627328T (lt) 2016-11-25
HUE031661T2 (en) 2017-07-28
US20130252965A1 (en) 2013-09-26
CN105193809B (zh) 2019-07-16
RS55332B1 (sr) 2017-03-31
CN105193809A (zh) 2015-12-30
IL225758A0 (en) 2013-06-27
KR20130101545A (ko) 2013-09-13
AU2011316225A1 (en) 2013-04-18
EP2627328A1 (en) 2013-08-21
IL225758A (en) 2017-03-30

Similar Documents

Publication Publication Date Title
CN103402514B (zh) 用于治疗运动障碍的血清素受体激动剂组合物
EP3897641B1 (en) Treatment of movement disorders
US20140243350A1 (en) Use of serotonin receptor agonists for treatment of movement disorders
US20140221385A1 (en) Combinations of serotonin receptor agonists for treatment of movement disorders
KR102527805B1 (ko) 부스피론 대사물의 용도
US11191758B2 (en) Use of selective serotonin 5-HT1A receptor agonists for treating side-effects of VMAT inhibitors
HK1188927B (en) Combinations of serotonin receptor agonists for treatment of movement disorders
HK1129593B (en) Use of kcnq-opener for the preparation of a pharmaceutical composition for treating schizophrenia

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C53 Correction of patent of invention or patent application
CB02 Change of applicant information

Address after: Copenhagen

Applicant after: CONCIT PHARMA APS

Address before: Denmark in Derup

Applicant before: Concit Pharma Aps

COR Change of bibliographic data

Free format text: CORRECT: APPLICANT; FROM: CONCIT PHARMA APS TO: KANGTELA PHARMA APS

C14 Grant of patent or utility model
GR01 Patent grant